Specialty Pharma Journal Specialty, Precision & Technology
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Nov. 15, 2018 (GLOBE NEWSWIRE) — uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet medical needs, today announced initial clinical data in patients treated in the Company’s Phase IIb dose-confirmation study of AMT-061, an investigational AAV5-based gene therapy containing …
Tag Archives: uniQure
November, 2018
January, 2017
-
31 January
FDA Grants Breakthrough Therapy Designation to uniQure’s Investigational Hemophilia B Drug
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Jan. 30, 2017 (GLOBE NEWSWIRE) — uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced that AMT-060, its proprietary, investigational gene therapy in patients with severe hemophilia B, has received Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA). This designation …
April, 2015
-
6 April
Bristol-Myers Squibb Enters Gene Therapy Deal with uniQure
Today, Bristol-Myers Squibb (BMS) announced that it has entered into a deal with uniQure for its gene therapy technology platform. The companies said that they have entered into an agreement that provides BMS with exclusive access to uniQure’s technology platform for multiple targets in cardiovascular diseases, as well as the …